What Is RMD Fair Value?
ResMed (RMD) fair value estimate using multiple valuation models, updated daily.
As of August 29, 2026, ResMed (RMD) has a composite fair value estimate of $146.05 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $240.33, suggesting the stock is overvalued by 39.2%.
Data as of August 29, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$146.05
vs. current price of $240.33(-39.2%)
How Is RMD Fair Value Calculated?
Four independent models estimate what RMD is worth. Each uses different inputs and assumptions. The composite blends them by weight.
RMD Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$189.89
-21.0%Overvalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$65.24
-72.9%Overvalued
Inputs used
RMD Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$111.42
-53.6%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$120.86
-49.7%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $240.33 is 21.0% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.24B | $1.15B |
| Year 2 | $1.35B | $1.15B |
| Year 3 | $1.47B | $1.15B |
| Year 4 | $1.60B | $1.15B |
| Year 5 | $1.74B | $1.16B |
| Year 6 | $1.89B | $1.16B |
| Year 7 | $2.06B | $1.16B |
| Year 8 | $2.24B | $1.17B |
| Year 9 | $2.44B | $1.17B |
| Year 10 | $2.65B | $1.17B |
| Terminal Value | $45.24B | $20.00B |
What Are RMD's Key Financial Metrics?
Earnings & Growth
Current Price
$240.33
EPS (TTM)
$10.62
Forward P/E
18.2
Profit Margin
26.9%
Cash & Balance Sheet
Free Cash Flow
939.2M
EBITDA
2.1B
Book Value
$45.66
Total Debt
825.9M
What Do Analysts Say About RMD?
Low
$175.00
Average
$245.50
High
$320.00
Upside
+2.2%
RMD Fair Value FAQ
What is the fair value of RMD?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), RMD's estimated fair value is $146.05. The stock is currently trading at $240.33, which makes it overvalued by our analysis.
How is RMD's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is RMD overvalued or undervalued?
Based on our analysis, RMD is overvalued. The current price of $240.33 is 39.2% above our estimated fair value of $146.05.
What do Wall Street analysts say about RMD?
16 analysts cover ResMed with a consensus rating of "Buy." The average price target is $245.50, ranging from $175.00 to $320.00. This implies 2.2% upside from the current price.